Literature DB >> 22257681

Neoplastic "Black Ops": cancer's subversive tactics in overcoming host defenses.

Arya Biragyn1, Dan L Longo.   

Abstract

Metastatic cancer is usually an incurable disease. Cancers have a broad repertoire of subversive tactics to defeat the immune system. They mimic self, they down-regulate MHC molecules so that T cells are blind to their presence, they interfere with antigen presentation, and they produce factors that can kill T cells or paralyze their response to antigens. Furthermore, the same powerful machinery designed to prevent harmful autoimmune responses is also acting to protect cancers. In particular, cancer is protected with the help of so-called regulatory immune cells. These unique subsets of cells, represented by almost every immune cell type, function to control responses of effector immune cells. In this review, we will discuss the evidence that cancer actively promotes cross-talk of regulatory immune cells to evade immunosurveillance. We will also discuss the role of a newly described cell type, regulatory B cells, by emphasizing their importance in suppression of antitumor immune responses. Thus, cancer not only directly suppresses immune function, but also recruits components of the immune system to become traitors and protect the tumor from immune attack. Published by Elsevier Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22257681      PMCID: PMC3288709          DOI: 10.1016/j.semcancer.2012.01.005

Source DB:  PubMed          Journal:  Semin Cancer Biol        ISSN: 1044-579X            Impact factor:   15.707


  171 in total

1.  Effector memory T cells, early metastasis, and survival in colorectal cancer.

Authors:  Franck Pagès; Anne Berger; Matthieu Camus; Fatima Sanchez-Cabo; Anne Costes; Robert Molidor; Bernhard Mlecnik; Amos Kirilovsky; Malin Nilsson; Diane Damotte; Tchao Meatchi; Patrick Bruneval; Paul-Henri Cugnenc; Zlatko Trajanoski; Wolf-Herman Fridman; Jérôme Galon
Journal:  N Engl J Med       Date:  2005-12-22       Impact factor: 91.245

2.  Breast cancer lung metastasis requires expression of chemokine receptor CCR4 and regulatory T cells.

Authors:  Purevdorj B Olkhanud; Dolgor Baatar; Monica Bodogai; Fran Hakim; Ronald Gress; Robin L Anderson; Jie Deng; Mai Xu; Susanne Briest; Arya Biragyn
Journal:  Cancer Res       Date:  2009-06-30       Impact factor: 12.701

3.  The bisphosphonate YM529 inhibits osteolytic and osteoblastic changes and CXCR-4-induced invasion in prostate cancer.

Authors:  Sotaro Miwa; Atsushi Mizokami; Evan T Keller; Russell Taichman; Jian Zhang; Mikio Namiki
Journal:  Cancer Res       Date:  2005-10-01       Impact factor: 12.701

Review 4.  An innate sense of danger.

Authors:  P Matzinger
Journal:  Semin Immunol       Date:  1998-10       Impact factor: 11.130

5.  B lymphocytes secreting IgG linked to latent transforming growth factor-beta prevent primary cytolytic T lymphocyte responses.

Authors:  D A Rowley; R M Stach
Journal:  Int Immunol       Date:  1998-03       Impact factor: 4.823

6.  Immune stimulatory receptor CD40 is required for T-cell suppression and T regulatory cell activation mediated by myeloid-derived suppressor cells in cancer.

Authors:  Ping-Ying Pan; Ge Ma; Kaare J Weber; Junko Ozao-Choy; George Wang; Bingjiao Yin; Celia M Divino; Shu-Hsia Chen
Journal:  Cancer Res       Date:  2009-12-08       Impact factor: 12.701

7.  Loss of new chemokine CXCL14 in tumor tissue is associated with low infiltration by dendritic cells (DC), while restoration of human CXCL14 expression in tumor cells causes attraction of DC both in vitro and in vivo.

Authors:  Galina V Shurin; Robert L Ferris; Robert Ferris; Irina L Tourkova; Lori Perez; Anna Lokshin; Levent Balkir; Bobby Collins; Gurkamal S Chatta; Michael R Shurin
Journal:  J Immunol       Date:  2005-05-01       Impact factor: 5.422

8.  Cutting edge: Regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation.

Authors:  Edward Y Woo; Heidi Yeh; Christina S Chu; Katia Schlienger; Richard G Carroll; James L Riley; Larry R Kaiser; Carl H June
Journal:  J Immunol       Date:  2002-05-01       Impact factor: 5.422

9.  Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine.

Authors:  Paola Filipazzi; Roberta Valenti; Veronica Huber; Lorenzo Pilla; Paola Canese; Manuela Iero; Chiara Castelli; Luigi Mariani; Giorgio Parmiani; Licia Rivoltini
Journal:  J Clin Oncol       Date:  2007-06-20       Impact factor: 44.544

Review 10.  Adoptive immunotherapy of cancer using CD4(+) T cells.

Authors:  Pawel Muranski; Nicholas P Restifo
Journal:  Curr Opin Immunol       Date:  2009-03-13       Impact factor: 7.486

View more
  14 in total

1.  Origin and pharmacological modulation of tumor-associated regulatory dendritic cells.

Authors:  Hua Zhong; Dmitriy W Gutkin; Baohui Han; Yang Ma; Anton A Keskinov; Michael R Shurin; Galina V Shurin
Journal:  Int J Cancer       Date:  2014-01-20       Impact factor: 7.396

2.  Galectin-3 Binding Protein Secreted by Breast Cancer Cells Inhibits Monocyte-Derived Fibrocyte Differentiation.

Authors:  Michael J V White; David Roife; Richard H Gomer
Journal:  J Immunol       Date:  2015-07-01       Impact factor: 5.422

3.  Cancer Immunoediting: Elimination, Equilibrium, and Immune Escape in Solid Tumors.

Authors:  Jacek R Wilczyński; Marek Nowak
Journal:  Exp Suppl       Date:  2022

4.  Immune heterogeneity and clinicopathologic characterization of IGFBP2 in 2447 glioma samples.

Authors:  Jinquan Cai; Qun Chen; Yuqiong Cui; Jiawei Dong; Meng Chen; Pengfei Wu; Chuanlu Jiang
Journal:  Oncoimmunology       Date:  2018-02-13       Impact factor: 8.110

5.  Covert operations: cancer's many subversive tactics in overcoming host defenses.

Authors:  Dan L Longo
Journal:  Trans Am Clin Climatol Assoc       Date:  2013

Review 6.  The invisible arm of immunity in common cancer chemoprevention agents.

Authors:  Edmond Marzbani; Carol Inatsuka; Hailing Lu; Mary L Disis
Journal:  Cancer Prev Res (Phila)       Date:  2013-08

7.  Nuclear FAK controls chemokine transcription, Tregs, and evasion of anti-tumor immunity.

Authors:  Alan Serrels; Tom Lund; Bryan Serrels; Adam Byron; Rhoanne C McPherson; Alexander von Kriegsheim; Laura Gómez-Cuadrado; Marta Canel; Morwenna Muir; Jennifer E Ring; Eleni Maniati; Andrew H Sims; Jonathan A Pachter; Valerie G Brunton; Nick Gilbert; Stephen M Anderton; Robert J B Nibbs; Margaret C Frame
Journal:  Cell       Date:  2015-09-24       Impact factor: 41.582

Review 8.  Non-Inflammasome Forming NLRs in Inflammation and Tumorigenesis.

Authors:  Irving Coy Allen
Journal:  Front Immunol       Date:  2014-04-22       Impact factor: 7.561

9.  Personalizing immunotherapy: Balancing predictability and precision.

Authors:  Zvia Agur; Stanimir Vuk-Pavlović
Journal:  Oncoimmunology       Date:  2012-10-01       Impact factor: 8.110

10.  Growth inhibition of different human colorectal cancer xenografts after a single intravenous injection of oncolytic vaccinia virus GLV-1h68.

Authors:  Klaas Ehrig; Mehmet O Kilinc; Nanhai G Chen; Jochen Stritzker; Lisa Buckel; Qian Zhang; Aladar A Szalay
Journal:  J Transl Med       Date:  2013-03-26       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.